Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

SEASONIQUE an extended cycle oral contraceptive

In August 2006 Shire entered into a license agreement in respect of Duramed Pharmaceuticals, Inc's ('Duramed') oral contraceptive, SEASONIQUE. Duramed markets SEASONIQUE in the US. Shire has the rights to market this product in a number of territories outside of North America, including the larger European markets.

On February 24, 2009, Shire and Duramed amended this agreement and it will terminate on December 31, 2009. Pursuant to this amendment, Shire agreed to return to Duramed its rights under the agreement effective February 24, 2009.

Projects in pre-clinical development

A number of projects are underway in the early stages of pre-clinical development for the Specialty Pharmaceuticals area.

Human Genetic Therapies

Treatments for Angioedema

FIRAZYR for hereditary angioedema ('HAE') in the US

FIRAZYR is a treatment for acute HAE which Shire added to the portfolio through its acquisition of a majority voting interest in Jerini during 2008. Jerini received a not approvable letter for FIRAZYR for use in the US from the FDA in April 2008, and met with FDA in December 2008 to discuss the development of FIRAZYR. It was agreed that an additional clinical study would be required before approval could be considered and that a complete response to the not approvable letter would be filed after completion of this study. This additional study will be initiated during the third quarter of 2009.

ERT

Velaglucerase alfa (GA-GCB) - for the treatment of Gaucher disease

Velaglucerase alfa is an enzyme replacement therapy being developed for the treatment of Gaucher disease. Shire has completed enrolment in a worldwide Phase 3 clinical program for velaglucerase alfa. This comprehensive development program includes the evaluation of velaglucerase alfa in nai
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 21, 2011 Cephalon, Inc. (NASDAQ: CEPH ... Consent Revocation Statement with the Securities and Exchange Commission ... proposals to remove Cephalon,s entire Board of Directors and ... mailed copies of the Statement to shareholders of record ...
... Collins Stewart LLC is pleased to announce the ... Beal Advisors and Liberty Tree Advisors. The purpose of ... and private equity transactions in the healthcare sector. Both ... healthcare advisory firms. Georgia Erbez – founder of Beal ...
... Calif., April 21, 2011 The Stanford University ... the initiation of a Phase 1/2a clinical trial ... allogeneic cell therapy product, SB623, on patients suffering ... For details regarding this clinical trial, please refer ...
Cached Biology Technology:Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 2Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 3Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 4Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 5Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 6Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 7Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 8Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 9Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 10Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 2Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 3Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability 2
(Date:4/23/2014)... to their resumes in an effort to aid the ... issues as genomic science transitions to bedside healthcare, a ... , Until now the plays of Karen H. Rothenberg ... by, their peers and others in the genomics community ... Oxford University Press, publication of the book The ...
(Date:4/23/2014)... Indiana University School of Public Health-Bloomington has bolstered the ... finding a strong association between heme iron, found only ... The study found that heme iron consumption increased the ... no association was found between nonheme iron, which is ... disease. , The study was published online ahead of ...
(Date:4/23/2014)... that male black widow spiders prefer their female mates ... mate preference by male spiders. , The ... Andrade, a professor in UTSC,s Department of Biological Sciences, ... that males overwhelmingly chose to mate with well-fed, unmated ... whether a potential mate is well-fed and unmated by ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2
... benefit from treatment with mixtures of customized antibodies. In ... National Academy of Sciences (USA), a team of Weizmann ... form a web that destroys the cancer cell's communication ... intensive cancer research led to the identification of a ...
... seem to occur on Earth roughly every 26 million ... be caused by rare collisions with comets or asteroids. ... that extraordinary predators are at fault instead. , Adam ... many species competing for both food and living space. ...
... to accurately measure the levels of important chemicals in ... level of a single cell. Scientists at the Carnegie ... the first to overcome this obstacle by successfully applying ... brain chemical levels. The sensors alter their 3-dimensional form ...
Cached Biology News:Two are better than one 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3